Hello, [...].
Do you wish to implement a symptom-based taper? If so, I suggest you plan your taper one reduction at a time. Why? Because you will be adjusting your plan on a regular basis depending on how you respond to reductions.
Is your prescriber willing to support a symptom-based taper? If not (or if you don’t know), I encourage you to read the Colorado Consortium’s Benzodiazepine Deprescribing Guidance Document (see link below). In a nutshell, what you want your prescriber to be aware of and agree to is the Tapering Principles in Section 3.
Depending on your relationship with your prescriber, you may find it helpful to share the entire document with him/her. It’s evidence-based, clear, concise, and current (published in 2022).
What dosage forms of zoplicone are available in your country? Tablets? What strength(s)? Are they scored? Liquid? What concentration(s)?
What test reduction amount do you wish to try? (The Colorado Consortium recommends an initial trial reduction of 5% or less.)
Link:
Benzodiazepine Deprescribing Guidance Document (target audience is prescribers)
https://corxconsortium.org/wp-content/uploads/Benzo-Deprescribing.pdf
